Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
1999-09-01
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem
cell transplant works in treating patients with lymphoma that has returned or does not
respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient
or a donor may be able to replace immune cells that were destroyed by chemotherapy used to
kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells
(graft-versus-tumor effect).
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Completed
Fred Hutchinson Cancer Research Center
Phase 1/Phase 2
1999-09-01
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem
cell transplant works in treating patients with lymphoma that has returned or does not
respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient
or a donor may be able to replace immune cells that were destroyed by chemotherapy used to
kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells
(graft-versus-tumor effect).
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
Terminated
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
2001-09-01
The purpose of this study is to find out if using a lower dose of chemotherapy before stem
cell transplantation can cure patients of sickle cell anemia or thalassemia while causing
fewer severe side effects than conventional high dose chemotherapy with transplantation.
No complete, reliable identification of the marketed drug “Oforta” (active ingredient, strength, dosage form, originator, or regulatory references such as FDA/EMA/NDA/BLA identifiers) is provided. Without that, clinical-trials status, competitive landscape, Orange Book/Bolar exposure, and market projections cannot be produced accurately.
Key Takeaways
Market and clinical-trials updates for “Oforta” cannot be generated without unambiguous product identity.
No defensible sales forecast, competitor mapping, or regulatory timeline can be computed without the active ingredient and regulatory label.
FAQs
What active ingredient is “Oforta” and what regulatory dossier does it map to?
Which phase trials (Phase 1/2/3) are currently enrolling or completed for Oforta?
What is the FDA/EMA status of Oforta and which review pathway was used?
What competing drugs target the same indication and how do their mechanisms compare?
What patent and exclusivity risks affect generic or biosimilar timing for Oforta?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
